Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 07/03/19
End: 04/30/26
Due: 04/30/27
Phase: N/A
Priority: Normal
Start: 10/22/19
End: 10/31/20
Due: 10/31/21
Phase: N/A
Priority: Normal
Start: 02/04/24
End: 08/31/27
Due: 08/31/28
Phase: N/A
Priority: Normal
Start: 03/06/19
End: 08/31/21
Due: 08/31/22
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Prospective Study to Evaluate Peginterferon in Reducing the Incidence of HCC in CHB Patients | NCT05671315 | Qing XIe | user2@example.com | None | 2019-07-03 | 2026-04-30 | 2027-04-30 | - | - | 2025-07-14 |
| Risk of Hepatocellular Carcinoma in Patients Treated With ETV vs TDF for Chronic Hepatitis B With Compensated Cirrhosis | NCT04160897 | Qing XIe | user2@example.com | None | 2019-10-22 | 2020-10-31 | 2021-10-31 | - | - | 2025-07-14 |
| Pegylated Interferon α in Previously Interferon-treated CHB（Leading Study） | NCT06323681 | Qing XIe | user2@example.com | None | 2024-02-04 | 2027-08-31 | 2028-08-31 | - | - | 2025-07-14 |
| Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C | NCT04952207 | Qing XIe | user2@example.com | None | 2019-03-06 | 2021-08-31 | 2022-08-31 | - | - | 2025-07-14 |